On 13 May 2026, Zydus Lifesciences announced that it has entered into a definitive agreement to acquire all outstanding shares of Assertio Holdings in an all-cash transaction valued at US$166.4 million.
Under the terms of the merger, Zydus will commence a tender offer to acquire the outstanding Assertio common stock. Following successful completion of the tender offer, Zydus will acquire all remaining shares through a second-step merger at the same price as the tender offer (US$23.50 per share). The transaction is expected to close in FY26/27.
Assertio’s portfolio includes Rolvedon® (eflapegrastim-xnst), which has received approval from the FDA for the prevention of febrile neutropenia in adult cancer patients receiving myelosuppressive chemotherapy. This acquisition will expand Zydus’ oncology capabilities and presence in the US.
Zydus entered the US biosimilar market in December 2025, with an exclusive licensing and supply agreement with Formycon for the commercialisation of biosimilar pembrolizumab, FYB206. Zydus has expressed its optimism that it will be the first company to file a BLA in the US for biosimilar pembrolizumab. Also in December 2025, Zydus partnered with Bioeq in relation to the US commercialisation rights to Nufymco®, an interchangeable biosimilar to Genentech’s Lucentis® (ranibizumab).